WA L D E N U N I V E R S I T Y · N U R S 6 5 2 1 ·
2026/2027 EDITION
100
Advanced Questions
Pharmacology 10
Sections
Final Examination 100%
Verified
Complete test bank with 100 verified questions and
comprehensive graded rationales covering
pharmacokinetics, pharmacodynamics, cardiovascular,
endocrine, CNS, antimicrobial, respiratory, GI, pain
management, special populations, and pharmacogenomics
aligned with Walden University NURS 6521 curriculum
standards.
Questions and Answers · Grade A · Verified
Latest Update
N U RS 6 5 2 1 A DVA N C E D P H A R M A C O L O GY · WA L D E N
UNIVERSITY FINAL EXAM TEST BANK
,Section 1: Pharmacokinetics and Pharmacodynamics Principles
ADME, Receptors, Dose-Response, Therapeutic Index, CYP450 (Q1-Q12)
Q1: A nurse practitioner is educating a patient about why their oral medication requires a higher dose than the same
drug given intravenously. The NP explains that the oral dose is partially metabolized in the liver before reaching
systemic circulation. Which pharmacokinetic process does this describe?
A. Bioavailability
B. First-pass metabolism [CORRECT]
C. Volume of distribution
D. Phase II conjugation
Correct Answer: B
Rationale: First-pass metabolism refers to the pre-systemic metabolism of a drug by the liver after oral absorption but before it reaches systemic
circulation, significantly reducing bioavailability. Bioavailability is the fraction of the administered dose that reaches systemic circulation, which is
reduced by first-pass metabolism. Volume of distribution describes how a drug distributes throughout body compartments. Phase II conjugation is a
metabolic pathway, not an absorption phenomenon. Drugs with high first-pass metabolism (e.g., propranolol, morphine) require higher oral doses to
achieve therapeutic effects.
Q2: A patient with chronic kidney disease is prescribed a medication that is primarily eliminated by glomerular
filtration. The nurse practitioner anticipates that the drug will require dosage adjustment. Which pharmacokinetic
parameter is most affected by decreased renal function?
A. Absorption rate
B. Distribution volume
C. Half-life [CORRECT]
D. Protein binding
Correct Answer: C
Rationale: Half-life (t1/2) is the pharmacokinetic parameter most directly affected by decreased renal function for drugs eliminated primarily by
glomerular filtration or tubular secretion. When renal clearance decreases, the elimination rate constant decreases, prolonging the half-life and
potentially leading to drug accumulation and toxicity. Absorption rate is unaffected by renal function. Volume of distribution may change slightly
but is less impactful. Protein binding can be altered in kidney disease but does not directly determine dosing intervals the way half-life does.
Q3: A nurse practitioner is prescribing a medication that is a CYP3A4 substrate to a patient who consumes
grapefruit juice daily. The NP expects which pharmacokinetic change?
A. Decreased drug metabolism and increased plasma levels [CORRECT]
B. Increased drug metabolism and decreased plasma levels
C. No effect on drug metabolism
D. Enhanced renal excretion of the drug
Correct Answer: A
Rationale: Grapefruit juice is a CYP3A4 inhibitor that decreases the metabolism of CYP3A4 substrates, leading to increased plasma drug levels and
potential toxicity. CYP3A4 metabolizes more than 50% of all drugs. This interaction is clinically significant for drugs such as statins, calcium
channel blockers, and benzodiazepines. Inducers like rifampin and St. John's Wort would have the opposite effect, increasing metabolism and
decreasing levels. Grapefruit juice does not affect renal excretion.
Q4: A patient with a known genetic polymorphism of CYP2D6 is classified as a poor metabolizer. The NP prescribes
codeine for pain management. What clinical outcome is most likely?
A. Enhanced pain relief due to higher morphine levels
B. No analgesic effect because codeine cannot be converted to its active metabolite [CORRECT]
C. Increased risk of serotonin syndrome
D. Rapid clearance of codeine with subtherapeutic levels
Correct Answer: B
Rationale: Codeine is a prodrug that requires conversion to morphine via CYP2D6 to produce analgesia. A CYP2D6 poor metabolizer cannot
efficiently convert codeine to its active metabolite, resulting in little to no pain relief. Ultra-rapid metabolizers would have the opposite problem,
producing excessive morphine and increased toxicity risk. This is a critical pharmacogenomic consideration. Serotonin syndrome requires
serotonergic agents, not codeine alone. Rapid clearance with subtherapeutic levels describes extensive metabolizers, not poor metabolizers.
, Q5: A drug has a narrow therapeutic index, and the NP needs to monitor serum drug levels to ensure efficacy while
preventing toxicity. Which medication requires therapeutic drug monitoring?
A. Amoxicillin
B. Lithium [CORRECT]
C. Metformin
D. Hydrochlorothiazide
Correct Answer: B
Rationale: Lithium has a narrow therapeutic index (0.6-1.2 mEq/L), requiring regular serum level monitoring to prevent toxicity (tremor, confusion,
seizures, coma) while maintaining therapeutic efficacy for bipolar disorder. Other narrow therapeutic index drugs include digoxin, warfarin,
phenytoin, and theophylline. Amoxicillin, metformin, and hydrochlorothiazide have wide therapeutic indices and do not require routine serum drug
monitoring. Narrow therapeutic index drugs have a small margin between effective and toxic doses.
Q6: A nurse practitioner is explaining the concept of a drug-receptor interaction to a nursing student. A drug that
binds to a receptor and produces the maximum possible response is classified as which type of agent?
A. Partial agonist
B. Antagonist
C. Full agonist [CORRECT]
D. Inverse agonist
Correct Answer: C
Rationale: A full agonist binds to a receptor and produces the maximum possible biological response, achieving full efficacy. A partial agonist binds
to the same receptor but produces only a submaximal response even at full receptor occupancy. An antagonist binds to the receptor but produces no
response and blocks agonist binding. An inverse agonist binds to the receptor and produces an effect opposite to that of the agonist. Understanding
receptor pharmacology is essential for predicting drug effects and selecting appropriate therapeutics.
Q7: A patient is prescribed warfarin, which is metabolized by CYP2C9. The NP reviews the medication list and
finds the patient is also taking an herbal supplement that is a CYP inducer. Which supplement would increase
warfarin metabolism and decrease its anticoagulant effect?
A. Grapefruit juice
B. Ketoconazole
C. St. John's Wort [CORRECT]
D. Fluconazole
Correct Answer: C
Rationale: St. John's Wort is a potent CYP inducer (particularly CYP3A4 and CYP2C9) that increases the metabolism of warfarin, decreasing its
anticoagulant effect and potentially leading to therapeutic failure. Grapefruit juice, ketoconazole, and fluconazole are CYP inhibitors that would
have the opposite effect, increasing warfarin levels and bleeding risk. Patients on warfarin should be counseled to avoid St. John's Wort and other
CYP inducers like rifampin, phenytoin, and carbamazepine.
Q8: The nurse practitioner explains to a patient that a drug has high protein binding (95%). Which pharmacokinetic
concept is most important for the NP to consider when adding a second highly protein-bound drug?
A. Increased renal clearance
B. Displacement interactions leading to increased free drug levels [CORRECT]
C. Decreased volume of distribution
D. Enhanced first-pass metabolism
Correct Answer: B
Rationale: Highly protein-bound drugs (>90%) are susceptible to displacement interactions when co-administered with other highly protein-bound
drugs. When a second drug displaces the first from protein binding sites, the free (active) fraction increases, potentially causing toxicity. Warfarin
and phenytoin are classic examples of highly protein-bound drugs prone to displacement interactions. This does not directly affect renal clearance
or volume of distribution. First-pass metabolism occurs before systemic distribution and is unrelated to protein binding displacement.
Q9: A nurse practitioner is calculating the time required for a drug to reach steady-state concentration. The patient
asks how long it will take. The NP correctly responds that steady state is achieved after approximately how many
half-lives?
A. 1-2 half-lives
B. 3-5 half-lives [CORRECT]
C. 10 half-lives
2026/2027 EDITION
100
Advanced Questions
Pharmacology 10
Sections
Final Examination 100%
Verified
Complete test bank with 100 verified questions and
comprehensive graded rationales covering
pharmacokinetics, pharmacodynamics, cardiovascular,
endocrine, CNS, antimicrobial, respiratory, GI, pain
management, special populations, and pharmacogenomics
aligned with Walden University NURS 6521 curriculum
standards.
Questions and Answers · Grade A · Verified
Latest Update
N U RS 6 5 2 1 A DVA N C E D P H A R M A C O L O GY · WA L D E N
UNIVERSITY FINAL EXAM TEST BANK
,Section 1: Pharmacokinetics and Pharmacodynamics Principles
ADME, Receptors, Dose-Response, Therapeutic Index, CYP450 (Q1-Q12)
Q1: A nurse practitioner is educating a patient about why their oral medication requires a higher dose than the same
drug given intravenously. The NP explains that the oral dose is partially metabolized in the liver before reaching
systemic circulation. Which pharmacokinetic process does this describe?
A. Bioavailability
B. First-pass metabolism [CORRECT]
C. Volume of distribution
D. Phase II conjugation
Correct Answer: B
Rationale: First-pass metabolism refers to the pre-systemic metabolism of a drug by the liver after oral absorption but before it reaches systemic
circulation, significantly reducing bioavailability. Bioavailability is the fraction of the administered dose that reaches systemic circulation, which is
reduced by first-pass metabolism. Volume of distribution describes how a drug distributes throughout body compartments. Phase II conjugation is a
metabolic pathway, not an absorption phenomenon. Drugs with high first-pass metabolism (e.g., propranolol, morphine) require higher oral doses to
achieve therapeutic effects.
Q2: A patient with chronic kidney disease is prescribed a medication that is primarily eliminated by glomerular
filtration. The nurse practitioner anticipates that the drug will require dosage adjustment. Which pharmacokinetic
parameter is most affected by decreased renal function?
A. Absorption rate
B. Distribution volume
C. Half-life [CORRECT]
D. Protein binding
Correct Answer: C
Rationale: Half-life (t1/2) is the pharmacokinetic parameter most directly affected by decreased renal function for drugs eliminated primarily by
glomerular filtration or tubular secretion. When renal clearance decreases, the elimination rate constant decreases, prolonging the half-life and
potentially leading to drug accumulation and toxicity. Absorption rate is unaffected by renal function. Volume of distribution may change slightly
but is less impactful. Protein binding can be altered in kidney disease but does not directly determine dosing intervals the way half-life does.
Q3: A nurse practitioner is prescribing a medication that is a CYP3A4 substrate to a patient who consumes
grapefruit juice daily. The NP expects which pharmacokinetic change?
A. Decreased drug metabolism and increased plasma levels [CORRECT]
B. Increased drug metabolism and decreased plasma levels
C. No effect on drug metabolism
D. Enhanced renal excretion of the drug
Correct Answer: A
Rationale: Grapefruit juice is a CYP3A4 inhibitor that decreases the metabolism of CYP3A4 substrates, leading to increased plasma drug levels and
potential toxicity. CYP3A4 metabolizes more than 50% of all drugs. This interaction is clinically significant for drugs such as statins, calcium
channel blockers, and benzodiazepines. Inducers like rifampin and St. John's Wort would have the opposite effect, increasing metabolism and
decreasing levels. Grapefruit juice does not affect renal excretion.
Q4: A patient with a known genetic polymorphism of CYP2D6 is classified as a poor metabolizer. The NP prescribes
codeine for pain management. What clinical outcome is most likely?
A. Enhanced pain relief due to higher morphine levels
B. No analgesic effect because codeine cannot be converted to its active metabolite [CORRECT]
C. Increased risk of serotonin syndrome
D. Rapid clearance of codeine with subtherapeutic levels
Correct Answer: B
Rationale: Codeine is a prodrug that requires conversion to morphine via CYP2D6 to produce analgesia. A CYP2D6 poor metabolizer cannot
efficiently convert codeine to its active metabolite, resulting in little to no pain relief. Ultra-rapid metabolizers would have the opposite problem,
producing excessive morphine and increased toxicity risk. This is a critical pharmacogenomic consideration. Serotonin syndrome requires
serotonergic agents, not codeine alone. Rapid clearance with subtherapeutic levels describes extensive metabolizers, not poor metabolizers.
, Q5: A drug has a narrow therapeutic index, and the NP needs to monitor serum drug levels to ensure efficacy while
preventing toxicity. Which medication requires therapeutic drug monitoring?
A. Amoxicillin
B. Lithium [CORRECT]
C. Metformin
D. Hydrochlorothiazide
Correct Answer: B
Rationale: Lithium has a narrow therapeutic index (0.6-1.2 mEq/L), requiring regular serum level monitoring to prevent toxicity (tremor, confusion,
seizures, coma) while maintaining therapeutic efficacy for bipolar disorder. Other narrow therapeutic index drugs include digoxin, warfarin,
phenytoin, and theophylline. Amoxicillin, metformin, and hydrochlorothiazide have wide therapeutic indices and do not require routine serum drug
monitoring. Narrow therapeutic index drugs have a small margin between effective and toxic doses.
Q6: A nurse practitioner is explaining the concept of a drug-receptor interaction to a nursing student. A drug that
binds to a receptor and produces the maximum possible response is classified as which type of agent?
A. Partial agonist
B. Antagonist
C. Full agonist [CORRECT]
D. Inverse agonist
Correct Answer: C
Rationale: A full agonist binds to a receptor and produces the maximum possible biological response, achieving full efficacy. A partial agonist binds
to the same receptor but produces only a submaximal response even at full receptor occupancy. An antagonist binds to the receptor but produces no
response and blocks agonist binding. An inverse agonist binds to the receptor and produces an effect opposite to that of the agonist. Understanding
receptor pharmacology is essential for predicting drug effects and selecting appropriate therapeutics.
Q7: A patient is prescribed warfarin, which is metabolized by CYP2C9. The NP reviews the medication list and
finds the patient is also taking an herbal supplement that is a CYP inducer. Which supplement would increase
warfarin metabolism and decrease its anticoagulant effect?
A. Grapefruit juice
B. Ketoconazole
C. St. John's Wort [CORRECT]
D. Fluconazole
Correct Answer: C
Rationale: St. John's Wort is a potent CYP inducer (particularly CYP3A4 and CYP2C9) that increases the metabolism of warfarin, decreasing its
anticoagulant effect and potentially leading to therapeutic failure. Grapefruit juice, ketoconazole, and fluconazole are CYP inhibitors that would
have the opposite effect, increasing warfarin levels and bleeding risk. Patients on warfarin should be counseled to avoid St. John's Wort and other
CYP inducers like rifampin, phenytoin, and carbamazepine.
Q8: The nurse practitioner explains to a patient that a drug has high protein binding (95%). Which pharmacokinetic
concept is most important for the NP to consider when adding a second highly protein-bound drug?
A. Increased renal clearance
B. Displacement interactions leading to increased free drug levels [CORRECT]
C. Decreased volume of distribution
D. Enhanced first-pass metabolism
Correct Answer: B
Rationale: Highly protein-bound drugs (>90%) are susceptible to displacement interactions when co-administered with other highly protein-bound
drugs. When a second drug displaces the first from protein binding sites, the free (active) fraction increases, potentially causing toxicity. Warfarin
and phenytoin are classic examples of highly protein-bound drugs prone to displacement interactions. This does not directly affect renal clearance
or volume of distribution. First-pass metabolism occurs before systemic distribution and is unrelated to protein binding displacement.
Q9: A nurse practitioner is calculating the time required for a drug to reach steady-state concentration. The patient
asks how long it will take. The NP correctly responds that steady state is achieved after approximately how many
half-lives?
A. 1-2 half-lives
B. 3-5 half-lives [CORRECT]
C. 10 half-lives
